Somalogic (SLGC) Reports Prelim FY22 Revenue of $93M-$98M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates
January 9, 2023 9:00 AM ESTBOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth.
In addition, SomaLogic is pleased to announce several organizational and strategic updates:
Newly signed agreement with Group 42 Healthcare (G42) to use SomaLogic as its sole proteomics provider for a world-class multi-omic research and healthcare initiative, expanding the Companys reach in international markets. The agreement spans... More